Latest news with #HumaTherapeutics
Yahoo
4 days ago
- Health
- Yahoo
Huma launches genAI clinical documentation tool
British healthtech company Huma Therapeutics has initiated the global launch of Hi Scribe, a generative AI (genAI) clinical documentation tool designed to automate and streamline the creation of clinical notes. Powered by over 60 million consultations conducted by eConsult, which Huma acquired last year, Hi Scribe is available through the Huma Cloud Platform (HCP), providing real time clinical documentation automation and the generation of structured clinical notes that can be directly integrated into electronic health record (EHR) systems. Hi Scribe is already launched in the UK to 870 practices, covering around 10 million patients, with write-back and coding capabilities for the EHR systems EMIS and SystmOne. Now rolling out across more than 4,500 health systems and clinics powered by Huma technologies, worldwide, Huma CEO and founder Dan Vahdat stated that administrative burdens such as process compliance and accurate billing remain some of the 'greatest challenges' facing healthcare systems globally. 'Hi Scribe gives clinicians critical time back, allowing them to focus on what matters most: their patients,' said Vahdat. Initiation of the tool's global launch follows the UK's National Health Service (NHS) England guidance around using AI-enabled scribing products in healthcare settings that was issued in April. Relating to best practices surrounding controls and implementation, the NHS guidelines advise healthcare systems to integrate such AI products with their principal EHR system and to ensure legal and regulatory requirements are factored into the procurement and implementation of their chosen products. Dr Murray Ellender, head of UK Healthcare at Huma commented: 'By leveraging genAI with strong regulatory governance, we are ensuring safe, effective, and efficient care. We are excited in the near future to start helping care providers with intelligent suggestions for next steps — ensuring that nothing is left unnoticed.' Huma recently announced a partnership with growth equity company Eckuity to support its development of technology infrastructure to support ongoing plans to acquire companies and launch digital solutions across the healthcare space. "Huma launches genAI clinical documentation tool" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
5 days ago
- Business
- Business Upturn
Huma Deploys Hi Scribe to Automate Clinical Documentation and Billing Using AI
New York, June 05, 2025 (GLOBE NEWSWIRE) — Huma Therapeutics, the global healthcare AI company, today announced the launch of Hi Scribe, a generative AI clinical documentation tool designed to automate and streamline the creation of clinical notes and supporting materials. Hi Scribe is built on top of the Huma AI foundation engine, known as Huma Intelligence (Hi), which also supports Hi Nurse (10X Nurse) and several other AI features. It is powered by insights from over 60 million consultations conducted by eConsult, one of Huma's portfolio companies acquired last year. Available within the Huma Cloud Platform (HCP), Hi Scribe automates clinical documentation in real-time, automatically generates structured clinical notes and enables direct integration into electronic health record (EHR) systems. It is designed for both in-person and virtual care settings, supporting clinicians across the full spectrum of digital health delivery. Already launched in the UK to 870 practices (covering 10 million patients) with writeback and coding capabilities for EMIS and SystmOne, the technology leverages Huma's strategic partnership with Google Cloud to deliver secure, scalable, and clinically compliant AI services to frontline healthcare workers. 'Administrative burdens—from documentation to process compliance and accurate billing—are among the greatest challenges facing healthcare systems globally,' said Dan Vahdat, CEO and Founder of Huma. 'Hi Scribe gives clinicians critical time back, allowing them to focus on what matters most: their patients. We're excited to roll this out across the 4,500+ health systems and clinics powered by Huma technologies around the world.' Regulatory-Compliant, Clinically Integrated Hi Scribe fully complies with regulations set forth by the UK Medicines and Healthcare products Regulatory Agency (MHRA) as a medical device and is part of Huma's globally compliant, enterprise-grade technology suite. It integrates directly into EHR systems, enabling clinicians to submit documentation seamlessly without disrupting workflow. As part of a broader care enablement strategy, Hi Scribe empowers clinicians with intelligent tools that reduce documentation burden while enhancing consistency and care quality. The launch follows recent NHS England guidance supporting the use of AI in clinical documentation and highlights Huma's role in driving innovation across public and private healthcare systems. With documentation consuming up to a third of clinical time globally, Huma is expanding access to Hi Scribe across its international footprint, which includes over 70 countries and 50 million engaged individuals. 'This tool brings clinicians' attention back to their patients,' said Dr. Murray Ellender, Head of UK Healthcare, Huma. 'By leveraging generative AI with strong regulatory governance, we are ensuring safe, effective, and efficient care. We are excited in the near future to start helping care providers with intelligent suggestions for next steps—ensuring that nothing is left unnoticed. We built this product in partnership with Opencast – a leading UK tech consultancy' 'Using Hi Scribe to transcribe my medical notes has transformed my day—saving me 2-3 minutes every consultation, reducing pressure, and letting me focus fully on my patients.' said Dr Ross Dyer-Smith, NHS GP. 'I have more headspace to think, listen, and make decisions. It's brought back more of the most satisfying part of practicing medicine—truly engaging and connecting with my patients.' U.S. Expansion with Wheel Huma's partner Wheel, the largest telemedicine provider-as-a-service platform in the U.S., will be among the first to bring Hi Scribe to virtual-first care environments in the U.S. through its Horizon platform. 'Clinicians shouldn't have to choose between delivering great care and managing documentation,' said Michelle Davey, CEO and Founder of Wheel. 'At Wheel, we're always looking for ways to make their jobs easier without adding friction. With Hi Scribe now integrated into Horizon, we're excited to be among the first to bring this kind of transformative AI technology to virtual care in the U.S.— giving our partners and their patients a better experience.' As Wheel brings Hi Scribe to market, it will be made available to enterprise organizations and digital health partners, expanding access to AI-powered documentation across U.S. virtual care delivery. Nationwide Rollouts Huma has also partnered with several countries to roll out this technology across all clinics as part of government-led digital health initiatives. Capturing clinical notes and automatically entering them into EMR systems remains a major challenge for many countries striving to accelerate the digitalization of their healthcare infrastructure. Ends Media images are here. About Huma Huma owns and operates leading digital and AI-first health products, including Aluna, myGP, GDm, eConsult, and more. All are supported by an AI-driven, software-defined, and federated-enabled operating model. Its portfolio powers over 4,500 hospitals and clinics, most major pharmaceutical companies, and CROs, with deployments across more than 70 countries. Huma's disease-agnostic cloud platform (HCP) is built for rapid, no-code configuration and seamless AI/ML integration. It has been recognized with FDA 510(k) Class II, EU MDR Class IIb, and other major regulatory certifications. These capabilities enable Huma to quickly launch new use cases and optimize acquired assets. Learn more at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
08-02-2025
- Business
- Yahoo
Starmer is driving Britain into ‘irrelevance', warns healthcare boss
Sir Keir Starmer is driving the UK into 'irrelevance', the boss of one of Britain's fastest-growing healthcare companies has warned. Dan Vahdat, chief executive of global healthcare firm Huma Therapeutics, said years of high taxes and a permanent aversion to risk had made the UK an increasingly uncompetitive place to do business. Huma, which worked with the NHS during the pandemic to help monitor Covid patients at home, is one of dozens of technology 'unicorns' in Britain – a start-up with a value of more than $1bn (£800m). However, Mr Vahdat said he was spending increasing amounts of time in the US, where Huma has announced a tie-up with pharmaceutical giant Pfizer. Mr Vahdat said the world's biggest economy had a better work ethic and deeper pots of cash to grow his business. The entrepreneur said he knew dozens of people who had left or were planning to leave the UK because of changes to Britain's non-dom regime, reforms that were started by the Tories and but deepened by Labour. He also rebuked Rachel Reeves's decision to increase business asset disposal relief to 18pc in 2026, which he said would discourage people from setting up new businesses. 'It started under the Conservatives but then obviously the new government changed it even more which has led almost everybody that I know – entrepreneurs and executives – saying they will leave by April this year because of inheritance tax. 'And that's not good. Because if you are in a place where all the executives are leaving, nobody else will want to come.' The Iranian-born entrepreneur also warned the Prime Minister that the UK could quickly be left behind in the AI race unless it sent a clearer message that Britain was open for business Mr Vahdat said: 'We cannot miss this, because if we miss this, we'll close our eyes and open it 10 years later and be so far behind. 'I have seen how a great country can go from all to nothing with my own eyes. From Egypt to Persia to the Ottoman Empire, they were all the greatest places. And now they're irrelevant. The UK has all the great foundations, including the talent, but every year we lose out, we lose more and it gets harder to bounce back.' Mr Vahdat said he remained loyal to the UK because it gave him a platform to set up a business. However, asked where he would list his company if given the opportunity today, Mr Vahdat said: 'From how things look like today, there isn't any point for us to list in the UK. 'Number one, it's the mindset of investors in the UK. They prefer dividends and to play it safe, they prefer low multiples. If you go and tell them I want to build the biggest healthcare company in the world they will laugh at you. 'But as laughable as it is, if that person doesn't give up, they may succeed and that is what the US is great for.' Sign in to access your portfolio
Yahoo
08-02-2025
- Business
- Yahoo
Starmer is driving Britain into ‘irrelevance', warns healthcare boss
Sir Keir Starmer is driving the UK into 'irrelevance', the boss of one of Britain's fastest-growing healthcare companies has warned. Dan Vahdat, chief executive of global healthcare firm Huma Therapeutics, said years of high taxes and a permanent aversion to risk had made the UK an increasingly uncompetitive place to do business. Huma, which worked with the NHS during the pandemic to help monitor Covid patients at home, is one of dozens of technology 'unicorns' in Britain – a start-up with a value of more than $1bn (£800m). However, Mr Vahdat said he was spending increasing amounts of time in the US, where Huma has announced a tie-up with pharmaceutical giant Pfizer. Mr Vahdat said the world's biggest economy had a better work ethic and deeper pots of cash to grow his business. The entrepreneur said he knew dozens of people who had left or were planning to leave the UK because of changes to Britain's non-dom regime, reforms that were started by the Tories and but deepened by Labour. He also rebuked Rachel Reeves's decision to increase business asset disposal relief to 18pc in 2026, which he said would discourage people from setting up new businesses. 'It started under the Conservatives but then obviously the new government changed it even more which has led almost everybody that I know – entrepreneurs and executives – saying they will leave by April this year because of inheritance tax. 'And that's not good. Because if you are in a place where all the executives are leaving, nobody else will want to come.' The Iranian-born entrepreneur also warned the Prime Minister that the UK could quickly be left behind in the AI race unless it sent a clearer message that Britain was open for business Mr Vahdat said: 'We cannot miss this, because if we miss this, we'll close our eyes and open it 10 years later and be so far behind. 'I have seen how a great country can go from all to nothing with my own eyes. From Egypt to Persia to the Ottoman Empire, they were all the greatest places. And now they're irrelevant. The UK has all the great foundations, including the talent, but every year we lose out, we lose more and it gets harder to bounce back.' Mr Vahdat said he remained loyal to the UK because it gave him a platform to set up a business. However, asked where he would list his company if given the opportunity today, Mr Vahdat said: 'From how things look like today, there isn't any point for us to list in the UK. 'Number one, it's the mindset of investors in the UK. They prefer dividends and to play it safe, they prefer low multiples. If you go and tell them I want to build the biggest healthcare company in the world they will laugh at you. 'But as laughable as it is, if that person doesn't give up, they may succeed and that is what the US is great for.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
